The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma

Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6:674–87. doi: 10.1038/nrc1934 .

Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002;31:339–46. doi: 10.1038/ng0802-339 .

Baylin SB, Ohm JE. Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006;6:107–16. doi: 10.1038/nrc1799 .

Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet. 2005;37:19–24. doi: 10.1038/ng1494 .

Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med. 2005;11:353–61. doi: 10.1016/j.molmed.2005.06.007 .

Hardie DG. The AMP-activated protein kinase pathway new players upstream and downstream. J Cell Sci. 2004;117:5479–87. doi: 10.1242/jcs.01540 .

Martin DE, Hall MN. The expanding TOR signaling network. Curr Opin Cell Biol. 2005;17:158–66. doi: 10.1016/j.ceb.2005.02.008 .

Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol. 2005;56:47–60. doi: 10.1016/j.critrevonc.2004.09.009 .

Shaw RJ, Bardeesy N, Manning BD. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell. 2004;6(1):91–9. doi: 10.1016/j.ccr.2004.06.007 .

Chan S. Targeting the mTOR: a new approach to treating cancer. Br J Cancer. 2004;91:1420–4. doi: 10.1038/sj.bjc.6602162 .

Ishak KG, Anthony PP, Sobin LH. Nonepithelial tumors. In: Ishak KG, editor. Histological typing of tumors of the liver. World Health Organization International Classification of Tumors. Berlin: Springer; 1994. pp. 22–7.

Wittekind C. Pitfalls in the classification of liver tumors. Pathologe. 2006;27:289–93. doi: 10.1007/s00292-006-0834-1 .

Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25:2586–93. doi: 10.1200/JCO.2006.09.4565 .

Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 2008;26:2707–16. doi: 10.1200/JCO.2007.15.6521 .

Pantuck AJ, Seligson DB, Klatte T. Prognostic relevance of the mTOR pathway in renal cell carcinoma. Cancer. 2007;109:2257–67. doi: 10.1002/cncr.22677 .

El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76. doi: 10.1053/j.gastro.2007.04.061 .

Blum H. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol. 2005;11:7391–400.

Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol. 2002;155:323–33. doi: 10.1093/aje/155.4.323 .

Hashimoto E, Taniai M, Kaneda H, Tokushige K, Hasegawa K, Okuda H. Comparison of hepatocellular carcinoma patients with alcoholic liver disease and nonalcoholic steatohepatitis. Alcohol Clin Exp Res. 2004;28:164S–8S.

Kurozawa Y, Ogimoto I, Shibata A, Nose T, Yoshimura T, Suzuki H. JACC Study Group. Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan. Br J Cancer. 2005;93:607–10. doi: 10.1038/sj.bjc.6602737 .

Maheshwari S, Sarraj A, Kramer J, El-Serag HB. Oral contraception and the risk of hepatocellular carcinoma. J Hepatol. 2007;47:506–13. doi: 10.1016/j.jhep.2007.03.015 .

Aravalli RN, Steer CJ, Cressman ENK. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008; 2047–63.

Zhou X, Tan M, Stone Hawthorne V. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 over expression predicts tumor progression in breast cancers. Clin Cancer Res. 2004;10:6779–88. doi: 10.1158/1078-0432.CCR-04-0112 .

Luo J, Manning BD, Cantley LC. Targeting the PI3 K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003;4:257–62. doi: 10.1016/S1535-6108(03)00248-4 .

Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4:335–48. doi: 10.1038/nrc1362 .

Pene F, Claessens Y-E, Muller O. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene. 2002;21:6587–97. doi: 10.1038/sj.onc.1205923 .

Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18:1926–45. doi: 10.1101/gad.1212704 .

Neshat MS, Mellinghoff IK, Tran C. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA. 2001;98:10314–9. doi: 10.1073/pnas.171076798 .

Wu FY, Wang SE, Sanders ME. Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity. Cancer Res. 2006;66:2162–72. doi: 10.1158/0008-5472.CAN-05-3304 .

Viglietto G, Motti ML, Bruni P. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med. 2002;8:1136–44. doi: 10.1038/nm762 .